A new study revealed safe MS treatment options during pregnancy, reassuring women to balance effective care with their plans ...

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...

Acadia Pharmaceuticals (ACAD) announced that the company has submitted a marketing authorization application to the European Medicines Agency ...

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for ...

Treating the growing problem of childhood obesity calls for exploring new approaches and treatments through well-designed ...

Acadia Pharma seeks European marketing approval for trofinetide for the treatment of Rett syndrome: San Diego Thursday, January 16, 2025, 13:00 Hrs [IST] Acadia Pharmaceuticals In ...

These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...

Samsung Group biotech unit is now Kospi's fourth-biggest company, outpacing world's largest CDMO, Lonza, in market cap ...

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide ...